Mandin H
Can Fam Physician. 2011; 31:329-31.
PMID: 21274105
PMC: 2327680.
Miller K
Drugs. 1994; 48(6):868-87.
PMID: 7533695
DOI: 10.2165/00003495-199448060-00004.
Rubin L, Lazar J
J Clin Invest. 1981; 67(1):193-200.
PMID: 7451649
PMC: 371587.
DOI: 10.1172/JCI110012.
Itoh S, Yamaba Y, Ichinoe A, Tsukada Y
Dig Dis Sci. 1980; 25(11):884-7.
PMID: 7438960
DOI: 10.1007/BF01338533.
Rigter H, Crabbe J, SCHONBAUM E
Naunyn Schmiedebergs Arch Pharmacol. 1980; 312(2):209-17.
PMID: 7402364
DOI: 10.1007/BF00569732.
Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype.
Shen D, Hosler J, Schroder R, AZARNOFF D
J Pharmacokinet Biopharm. 1980; 8(1):53-68.
PMID: 7381691
DOI: 10.1007/BF01059448.
Cardiovascular effects in man of intravenous prizidilol hydrochloride (SK&F 92657); a new antihypertensive agent.
EDMONSTONE W, Manghani K, Bell A, McLeod M, Burland W
Br J Clin Pharmacol. 1981; 12(4):567-72.
PMID: 7295490
PMC: 1401881.
DOI: 10.1111/j.1365-2125.1981.tb01266.x.
Fixed combination drug therapy.
Shenfield G
Drugs. 1982; 23(6):462-80.
PMID: 7049658
DOI: 10.2165/00003495-198223060-00003.
Clinical pharmacokinetics of hydralazine.
Ludden T, McNay Jr J, Shepherd A, Lin M
Clin Pharmacokinet. 1982; 7(3):185-205.
PMID: 7047041
DOI: 10.2165/00003088-198207030-00001.
Adverse effects of antihypertensive drugs.
Husserl F, Messerli F
Drugs. 1981; 22(3):188-210.
PMID: 7021123
DOI: 10.2165/00003495-198122030-00002.
The approach to the treatment of hypertensive patients with renal parenchymal disease.
Mailloux L, Bluestone P, Mossey R
Bull N Y Acad Med. 1982; 58(2):170-7.
PMID: 6956403
PMC: 1805303.
Cardiovascular effects of indoramin in man--a dose ranging study.
Nicholls D, Harron D, Shanks R
Br J Clin Pharmacol. 1983; 15(1):31-6.
PMID: 6849741
PMC: 1427821.
DOI: 10.1111/j.1365-2125.1983.tb01459.x.
Cardiovascular effects of alinidine and propranolol alone and in combination with hydralazine in normal man.
Nicholls D, Harron D, Shanks R
Br J Clin Pharmacol. 1983; 15(1):21-9.
PMID: 6849740
PMC: 1427818.
DOI: 10.1111/j.1365-2125.1983.tb01458.x.
Pinacidil, a new vasodilator: pharmacokinetics and pharmacodynamics of a new retarded release tablet in essential hypertension.
Carlsen J, Kardel T, Jensen H, Tango M, TRAP-JENSEN J
Eur J Clin Pharmacol. 1983; 25(4):557-61.
PMID: 6653652
DOI: 10.1007/BF00542128.
Vasodilator therapy in chronic congestive heart failure.
Schwartz A, Chatterjee K
Drugs. 1983; 26(2):148-73.
PMID: 6349967
DOI: 10.2165/00003495-198326020-00003.
Effects of intravenous endralazine in essential hypertension.
Hoffmann J, Thien T, van TLaar A
Br J Clin Pharmacol. 1983; 16(1):39-44.
PMID: 6349669
PMC: 1427955.
DOI: 10.1111/j.1365-2125.1983.tb02141.x.
Hydralazine-induced peripheral neuropathy seen in a Japanese slow acetylator patient.
Tsujimoto G, Horai Y, Ishizaki T, Itoh K
Br J Clin Pharmacol. 1981; 11(6):622-5.
PMID: 6268134
PMC: 1402188.
DOI: 10.1111/j.1365-2125.1981.tb01181.x.
A radionuclide method for the simultaneous study of the effects of drugs on central and peripheral haemodynamics.
Wathen C, Hannan W, Adie C, Muir A
Br J Clin Pharmacol. 1983; 16(1):45-50.
PMID: 6224502
PMC: 1427954.
DOI: 10.1111/j.1365-2125.1983.tb02142.x.
Hypertension in pregnancy. Pathophysiology and management.
Lubbe W
Drugs. 1984; 28(2):170-88.
PMID: 6147240
DOI: 10.2165/00003495-198428020-00005.
Differential blockade of alpha-adrenoceptors by indoramin.
Nicholls D, OConnor P, Harron D, Leahey W, Shanks R
Br J Clin Pharmacol. 1984; 17(6):719-28.
PMID: 6146328
PMC: 1463427.
DOI: 10.1111/j.1365-2125.1984.tb02409.x.
